Clinical Trials
81
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (75 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Target Recruit Count
- 36
- Registration Number
- NCT07097259
- Locations
- 🇺🇸
ICON Early Phase Services, LLC_Clinic San Antonio, San Antonio, Texas, United States
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 54
- Registration Number
- NCT06719973
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Merck Healthcare KGaA
- Target Recruit Count
- 51
- Registration Number
- 2024-517818-15-00
- Locations
- 🇺🇸
University of California - Los Angeles - 300208353, Santa Monica, California, United States
🇺🇸Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸Prisma Health Cancer Institute, ITOR, CRU, Greenville, South Carolina, United States
Anti-GD2 ADC M3554 in Advanced Solid Tumors
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-07-29
- Target Recruit Count
- 52
- Registration Number
- NCT06641908
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc, New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Conditions
- Advanced solid tumors and colorectal cancer
- Interventions
- Drug: Granulocyte colony stimulating factor (G-CSF)
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Merck Healthcare KGaA
- Target Recruit Count
- 59
- Registration Number
- 2024-514155-15-00
- Locations
- 🇪🇸
Hospital Quironsalud Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Quironsalud Madrid, Pozuelo De Alarcon, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 17
- Next